Proposal to award market share for permanent coronary drug eluting stents in DHBs
Source: Pharmac What we’re proposing PHARMAC is seeking feedback on a proposal to award Hospital Supply Status for permanent coronary drug eluting stents (“DES”) in DHBs through a provisional agreement with Abbott Laboratories NZ Limited (“Abbott”). It is proposed that: from 1 March 2019 Abbott’s brands of DES, Xience Xpedition and Xience Alpine would be […]
Read More →Proposal to list haemodialysis products supplied by BSN Medical Limited
Source: Pharmac What we’re proposing PHARMAC is seeking feedback on a proposal to list a range of haemodialysis equipment and products (“Haemodialysis Products”) in Part III of Section H of the Pharmaceutical Schedule from 1 February 2019, through a provisional agreement with BSN Medical Limited (“BSN Medical”). Consultation closes at 5pm on Tuesday, 4 December 2018 and […]
Read More →Proposal to list interventional radiology products supplied by Edwards Lifesciences (New Zealand) Ltd
Source: Pharmac What we’re proposing PHARMAC is seeking feedback on a proposal to list a range of interventional radiology products in Part III of Section H of the Pharmaceutical Schedule from 1 February 2019 through a provisional agreement with Edwards Lifesciences (New Zealand) Ltd (‘‘Edwards’’). Consultation closes at 5pm on Friday, 30 November 2018 and […]
Read More →Decision to list interventional radiology products supplied by Bard Australia Pty Ltd
Source: Pharmac What we are doing We are pleased to announce the approval of a listing agreement for a range of interventional radiology products with Bard Australia Pty Ltd (“Bard”). In summary this will result in: 1227 Interventional Radiology products from Bard being listed in Part III of Section H of the Pharmaceutical Schedule from 1 […]
Read More →Proposal for colecalciferol (vitamin D) oral liquid
Source: Pharmac What we’re proposing We propose to list colecalciferol (vitamin D) oral liquid (brand name Puria) from 1 January 2019. Consultation closes at 5 pm on Friday, 16 November 2018 and feedback can be emailed to alexander.rodgers@pharmac.govt.nz. What would the effect be? This proposal would list colecalciferol oral liquid in the community and hospital setting […]
Read More →Decision to list needles and syringes, and respiratory equipment supplied by REM SYSTEMS Limited
Source: Pharmac What we are doing We’re pleased to announce the approval of a listing agreement for supply of needles and syringes, and respiratory equipment (“respiratory care products”) with REM SYSTEMS (“REM”) Limited. In summary this will result in: REM’s needles and syringes and respiratory care products being listed on the Pharmaceutical Schedule from 1 […]
Read More →October 2018 tender notification
Source: Pharmac 31 October 2018 PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for one product included in the 2017/18 Invitation to Tender, dated 2 November 2017. Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject […]
Read More →Proposal to change how discarded medicines are reimbursed
Source: Pharmac What we’re proposing PHARMAC is seeking feedback on a proposal to change how we reimburse discarded medicines (“wastage”) in community pharmacies. The wastage rule is applied to some products in Section B of the Pharmaceutical Schedule to ensure that community pharmacies are reimbursed for the full cost of a pack. Over time, as […]
Read More →Update on proposal to move to one funded brand of lamotrigine (Logem)
Source: Pharmac Update PHARMAC would like to thank everyone who provided feedback on a proposal to move to one funded brand of lamotrigine (Logem). This was the subject of a consultation letter dated 29 August 2018, with a closing date for feedback of 26 September 2018. After reviewing the feedback, we have determined that we […]
Read More →Decision to list urology, ostomy and continence products supplied by Coloplast Pty Ltd and Liberty Medical NZ Limited
Source: Pharmac What we’re doing We are pleased to announce the approve of non-exclusive listing agreements with Coloplast Pty Ltd and Liberty Medical NZ Limited for the supply of urology, ostomy and continence products to DHBs. In summary, this will result in: Coloplast’s urology, ostomy and continence products being listed in Part III of Section […]
Read More →Further update on proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis C
Source: Pharmac Update This is a further update on the proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis C. PHARMAC would like to again thank everyone who gave feedback in response to our consultation letter about this proposal, dated 20 July 2018. PHARMAC provided an update on this proposal on 27 August 2018, which […]
Read More →Decision to modify the transition between funded brands in the Schedule
Source: Pharmac Important dates The changes to the transition period will first be reflected in the 2018/19 Invitation to Tender which is due to be released at the beginning of November 2018. The Invitation to Tender document will be amended to reflect the approved changes to the transition period. The anticipated dates the changes would […]
Read More →Decision to fund MiniMed 640G and Tandem t:slim X2 insulin pumps and consumables
Source: Pharmac What we are doing We’re pleased to announce a decision to list the MiniMed 640G insulin pump and the Tandem t:slim X2 insulin pump and associated consumables from 1 November 2018 for people who meet the Special Authority criteria for access to funded insulin pumps and consumables. There will be no changes to […]
Read More →Proposal to award sole supply and change some antiretroviral brands
Source: Pharmac What we’re proposing PHARMAC is seeking feedback on a proposal to make several changes to funding of antiretroviral therapies (ARTs) used in the treatment of HIV infection. Award sole supply and change brands for three ARTs; and Award sole supply and maintain existing brands for four ARTs. Brand changes would have a transition […]
Read More →Agreement for the supply of custom designed orthopaedic implants and associated design services supplied by Ossis Limited
Source: Pharmac What we’re doing We are pleased to announce the approval of a listing agreement with Ossis Limited (“Ossis”) for the supply of a range of custom designed orthopaedic implants and associated implant design services (“Orthopaedic Products”) to DHBs. In summary, this will result in: Pharmaceutical Schedule listings for a range of Orthopaedic Products […]
Read More →Decision to list interventional radiology products supplied by Teleflex Medical New Zealand Limited
Source: Pharmac What we are doing We are pleased to announce the approval of a listing agreement for a range of interventional radiology products with Teleflex Medical New Zealand Limited (“Teleflex”). In summary this will result in: Listing 109 Interventional Radiology products from Teleflex in Part III of Section H of the Pharmaceutical Schedule from […]
Read More →Proposal to decrease price and award sole supply for alendronate
Source: Pharmac What we’re proposing PHARMAC is seeking feedback on a proposal to award sole supply to the currently listed brand of alendronate sodium 70 mg tablets (Fosamax and Fosamax Plus), a treatment for osteoporosis. Price reductions would take effect from 1 February 2019 and this proposal would mean there would be no brand change […]
Read More →Evidence-based approach to funding choices more important than ever
Source: Pharmac Cancer will affect almost all New Zealanders at some point in their lives. Given the range of new treatments in the pipeline, PHARMAC works hard to fund the best medicines it can based on the evidence, says Sarah Fitt, Chief Executive. We all know someone who is, or might be, affected by some […]
Read More →RFP – PHARMAC and HRC research partnership 2019
Source: Pharmac 8 October 2018 PHARMAC and the Health Research Council of New Zealand request research proposals. PHARMAC and the Health Research Council of New Zealand have formed a joint research initiative to support innovative research and advance the strategic objectives of both organisations. This partnership will augment PHARMAC’s focus on securing best health outcomes from […]
Read More →Proposal to list medical devices supplied by REM SYSTEMS Limited
Source: Pharmac What we’re proposing PHARMAC is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 December 2018, through a provisional agreement with REM SYSTEMS Limited. Product ranges to include: needles and syringes; and respiratory equipment and consumables (“respiratory care products”). […]
Read More →